CAS 886045-05-2 | GPX-150-003 : Camsirubicin
(World's Largest Pharmaceutical Supplier)

CAS 886045-05-2, also known as afatinib dimaleate, is a medication used in the treatment of certain types of cancer. It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking the action of specific proteins that are involved in the growth and spread of cancer cells.

Afatinib dimaleate was approved for use by the United States Food and Drug Administration (FDA) in 2013, and has since become widely prescribed. It is typically used to treat non-small cell lung cancer that has specific mutations in the epidermal growth factor receptor (EGFR) gene.

In addition to its primary use in treating cancer, afatinib dimaleate has also been investigated for its potential use in treating other conditions. For example, some studies have suggested that it may be beneficial in treating head and neck squamous cell carcinoma, a type of cancer that affects the lining of the mouth and throat.

Like all medications, afatinib dimaleate can cause side effects. Some common side effects include diarrhea, rash, and nail changes. In rare cases, it may also cause serious side effects such as severe skin reactions, liver damage, or interstitial lung disease.

Despite its potential side effects, afatinib dimaleate has been shown to be an effective treatment for certain types of cancer, helping to slow or stop the growth and spread of cancer cells. As such, it is a valuable tool in the management of these diseases, and continues to be an important area of research and development in the field of oncology.